M&A Deal Summary |
|
|---|---|
| Date | 2014-03-06 |
| Target | Laboratorios BIAGRO S.A. |
| Sector | Chemicals |
| Buyer(s) | Bayer |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1863 |
| Sector | Life Science |
| Employees | 89,556 |
| Revenue | 46.6B EUR (2024) |
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer was founded in 1863 and is based in Leverkusen, Germany.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 20 |
| Sector: Chemicals M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 6 of 17 |
| Country: Argentina M&A | 1 of 1 |
| Year: 2014 M&A | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-12-19 |
Algeta ASA
Oslo, Norway Algeta ASA, an oncology company. |
Buy | $2.9B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-05-15 |
Bayer HealthCare - Interventional Division
Minneapolis, Minnesota, United States Bayer HealthCare - Interventional Division Offers a number of innovative technologies designed to treat coronary and peripheral vascular disease. The transaction includes the AngioJet Thrombectomy System and the Fetch 2 Aspiration Catheter, which use endovascular techniques to remove blood clots from blocked arteries and veins, and the JetStream Atherectomy System, a minimally invasive device used to remove plaque from diseased peripheral arteries. |
Sell | $415M |
